We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Launches New TaqPath Panel in Europe
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) recently announced the European launch of its TaqPath Enteric Bacterial Select Panel, which helps detect common gastrointestinal (GI) bacteria. This launch came on the heels of the European CE-IVD mark for the device earlier. This panel was validated and registered under IVDD in May 2022.
More About TaqPath Panel
This panel, apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast. This newly-launched test uses polymerase chain reaction (PCR) technology to analyze stool samples for a range of common GI bacteria, including Salmonella spp.; Shigella spp./enteroinvasive E. coli (EIEC); Campylobacter jejuni, Campylobacter coli, and Campylobacter upsaliensis.
Per the press release, testing using the TaqPath Enteric Bacterial Select Panel can be done in one test tube and can be scaled up to fit the needs of the lab by enabling up to 93 samples to be tested in one run. When conducted on Thermo Fisher’s QuantStudio 5 and QuantStudio 5 Dx systems, results from samples are interpreted and generated automatically. This helps in saving laboratorians’ time so they can focus on other tasks.
How is This Test Superior?
According to Thermo Fisher, this TaqPath Enteric Bacterial Select Panel is able to reliably return results in about two hours with more than 98% sensitivity and specificity. This compares to culturing samples in a laboratory, which can take up to two weeks to deliver results.
Image Source: Zacks Investment Research
Thermo Fisher claims that this advanced panel’s ability to identify and differentiate between the most common diarrhea-causing pathogens will make testing more accessible, providing laboratorians with more agility when identifying GI bacteria. With the specificity of the panel to detect different pathogens in a single test, this panel can preserve precious lab resources while providing critical information about the patient needed for the right treatment option.
Thermo Fisher International Operations Update
Thermo Fisher boasts strong international operations. It has witnessed consistent growth in the high-growth and emerging markets. In the second quarter of 2022, Asia Pacific grew in low double digits, with China growing over 20%. Growth in China was primarily driven by increasing demand for COVID-19 testing through the second quarter.
Share Price Performance
Thermo Fisher has outperformed its industry in the past year. The stock lost 11.3% compared with the industry’s 34% fall.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , ShockWave Medical, Inc. (SWAV - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
AMN Healthcare has lost 7.1% compared with the industry’s 36.1% fall in the past year.
ShockWave Medical, sporting a Zacks Rank #1 at present, has an estimated growth rate of 33.1% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has gained 33.9% against the industry’s 32.5% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.1%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 71.8% against the industry’s 15.7% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Thermo Fisher (TMO) Launches New TaqPath Panel in Europe
Thermo Fisher Scientific (TMO - Free Report) recently announced the European launch of its TaqPath Enteric Bacterial Select Panel, which helps detect common gastrointestinal (GI) bacteria. This launch came on the heels of the European CE-IVD mark for the device earlier. This panel was validated and registered under IVDD in May 2022.
More About TaqPath Panel
This panel, apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast. This newly-launched test uses polymerase chain reaction (PCR) technology to analyze stool samples for a range of common GI bacteria, including Salmonella spp.; Shigella spp./enteroinvasive E. coli (EIEC); Campylobacter jejuni, Campylobacter coli, and Campylobacter upsaliensis.
Per the press release, testing using the TaqPath Enteric Bacterial Select Panel can be done in one test tube and can be scaled up to fit the needs of the lab by enabling up to 93 samples to be tested in one run. When conducted on Thermo Fisher’s QuantStudio 5 and QuantStudio 5 Dx systems, results from samples are interpreted and generated automatically. This helps in saving laboratorians’ time so they can focus on other tasks.
How is This Test Superior?
According to Thermo Fisher, this TaqPath Enteric Bacterial Select Panel is able to reliably return results in about two hours with more than 98% sensitivity and specificity. This compares to culturing samples in a laboratory, which can take up to two weeks to deliver results.
Image Source: Zacks Investment Research
Thermo Fisher claims that this advanced panel’s ability to identify and differentiate between the most common diarrhea-causing pathogens will make testing more accessible, providing laboratorians with more agility when identifying GI bacteria. With the specificity of the panel to detect different pathogens in a single test, this panel can preserve precious lab resources while providing critical information about the patient needed for the right treatment option.
Thermo Fisher International Operations Update
Thermo Fisher boasts strong international operations. It has witnessed consistent growth in the high-growth and emerging markets. In the second quarter of 2022, Asia Pacific grew in low double digits, with China growing over 20%. Growth in China was primarily driven by increasing demand for COVID-19 testing through the second quarter.
Share Price Performance
Thermo Fisher has outperformed its industry in the past year. The stock lost 11.3% compared with the industry’s 34% fall.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , ShockWave Medical, Inc. (SWAV - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 7.1% compared with the industry’s 36.1% fall in the past year.
ShockWave Medical, sporting a Zacks Rank #1 at present, has an estimated growth rate of 33.1% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has gained 33.9% against the industry’s 32.5% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.1%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 71.8% against the industry’s 15.7% fall over the past year.